The cord blood banking industry has been around for over 30 years, focusing on acquiring units for use in hematopoietic stem cell transplant. Recent research indicates that cord blood can be a valuable source of naïve cells for cell therapy manufacturing. Cord blood banks are evolving their processes to accommodate the use of cord blood units for these new and evolving purposes. This helps developers understand the legacy constraints and complexities that banks are subject to as they strive to help cell therapy developers navigate the sourcing of this valuable resource.
This webinar will highlight cord blood bank capabilities and provide insight into current banking practices and considerations for developers as they consider using cord blood as a starting material for further manufacture.
- Understanding the current banking practices and additional capabilities, including consistencies or divergence between cord blood banks
- Discover how requests to modify current banking practices may impact the feasibility and/or scalability of sourcing cord blood units
- Insights into how and why developers should consider the use of cord blood units as a cell therapy starting material
PRESENTERS
Joy Aho
Director of Product Management and Strategy at NMDP BioTherapies
Amanda Conerty
Executive Director, Process, Analytical Development and Manufacturing at Artivia Biotherapeutics
Sara Shields
Associate Processing Facility Director at Cleveland Cord Blood Center
Luis Hernandez
Director of Cellular Therapies at LifeSouth Community Blood Centers